NCT06626282 Fertility and Ovarian Reserve in Female Childhood Cancer Survivors
| NCT ID | NCT06626282 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Liege |
| Condition | Childhood Cancer Survivors |
| Study Type | OBSERVATIONAL |
| Enrollment | 340 participants |
| Start Date | 2024-10-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 340 participants in total. It began in 2024-10-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.
Eligibility Criteria
Inclusion Criteria: * Child and adolescent female patients included in the Paediatrics Late Effects Project: * diagnosed with cancer1 between 01/01/2004 and 31/12/2018 * \<17 years old at diagnosis * treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF * alive * ≥ 18 years-old at time of recruitment. Exclusion Criteria: * Cancer diagnosis for controls
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06626282 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 50 Years, studying Childhood Cancer Survivors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06626282 currently recruiting?
Yes, NCT06626282 is actively recruiting participants. Contact the research team at bianca.andreea.david@citadelle.be for enrollment information.
Where is the NCT06626282 trial being conducted?
This trial is being conducted at Liège, Belgium, Brussels, Belgium, Brussels, Belgium.
Who is sponsoring the NCT06626282 clinical trial?
NCT06626282 is sponsored by Centre Hospitalier Universitaire de Liege. The trial plans to enroll 340 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.